| 產(chǎn)品編號 | bs-4592R-Bio |
| 英文名稱 | Rabbit Anti-P14ARF/Biotin Conjugated antibody |
| 中文名稱 | 生物素標(biāo)記的抑癌基因p16/p14/P19抗體 |
| 別 名 | CDKN2A; p16INK4a; INK4; P16INK4; ARF; CCM2; CDK4 Inhibitor; CDK4 inhibitor p16 INK4; CDK4I; CDKN2; CDKN2A; Cell cycle negative regulator beta; CMM2; Cyclin dependent kinase 4 inhibitor A; Cyclin dependent kinase inhibitor 2A (melanoma p16 inhibits CDK4); Cyclin Dependent Kinase Inhibitor 2A; Cyclin dependent kinase inhibitor 2A isoform 4; Cyclin dependent kinase inhibitor 2A isoforms 1/2/3; Cyclin dependent kinase inhibitor p16; INK4A; MLM; MTS1; Multiple tumor suppressor 1; Multiple Tumor Supressor 1; p14; p14(ARF); p14ARF; p16; p16 INK4; p16INK4; p16INK4a; p19; p19(ARF); p19Arf; TP16. |
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 免疫學(xué) 信號轉(zhuǎn)導(dǎo) 表觀遺傳學(xué) |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | (predicted: Human, ) |
| 產(chǎn)品應(yīng)用 | ELISA=1:100-1000 IHC-P=1:50-200 IHC-F=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 15kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human P16/CDKN2A |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: The CDKN2A locus gives rise to 2 distinct transcripts from different promoters. The transcripts have been designated p16(INK4A) and p14(ARF). This chromosomal region undergoes a number of inversions, translocations, heterozygous deletions, and homozygous deletions in a variety of malignant cell lines including those from glioma, non-small cell lung cancer, leukemia, and melanoma. Deletion of the region containing CDKN2A is found in more than half of all melanoma cell lines. In spite of the structural and some functional differences, all the proteins encoded by the CDKN2A gene are involved in cell cycle G1 control. Function: Capable of inducing cell cycle arrest in G1 and G2 phases. Acts as a tumor suppressor. Binds to MDM2 and blocks its nucleocytoplasmic shuttling by sequestering it in the nucleolus. This inhibits the oncogenic action of MDM2 by blocking MDM2-induced degradation of p53 and enhancing p53-dependent transactivation and apoptosis. Also induces G2 arrest and apoptosis in a p53-independent manner by preventing the activation of cyclin B1/CDC2 complexes. Binds to BCL6 and down-regulates BCL6-induced transcriptional repression. Binds to E2F1 and MYC and blocks their transcriptional activator activity but has no effect on MYC transcriptional repression. Binds to TOP1/TOPOI and stimulates its activity. This complex binds to rRNA gene promoters and may play a role in rRNA transcription and/or maturation. Interacts with NPM1/B23 and promotes its polyubiquitination and degradation, thus inhibiting rRNA processing. Interacts with COMMD1 and promotes its 'Lys63'-linked polyubiquitination. Interacts with UBE2I/UBC9 and enhances sumoylation of a number of its binding partners including MDM2 and E2F1. Binds to HUWE1 and represses its ubiquitin ligase activity. May play a role in controlling cell proliferation and apoptosis during mammary gland development. Subunit: Does not interact with cyclins, CDK1, CDK2, CDK4, CDK5 or CDK6. Binds to BCL6, E2F1, HUWE1, MDM2, MYC, NPM1/B23, TOP1/TOPOI and UBE2I/UBC9. Interacts with TBRG1 and COMMD1. Interacts with CDKN2AIP and E4F1. Subcellular Location: Nucleus, nucleolus. Nucleus, nucleoplasm. Post-translational modifications: Ubiquitinated in normal cells by TRIP12 via the ubiquitin fusion degradation (UFD) pathway, a process that mediates ubiquitination at the N-terminus, regardeless of the absence of lysine residues. Ubiquitination leads to its degradation. In cancer cells, however, TRIP12 is located in a different cell compartment, preventing ubiquitination and degradation. Database links: Entrez Gene: 1029 Human Omim: 600160 Human SwissProt: P42771 Human SwissProt: Q8N726 Human Unigene: 512599 Human Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 細(xì)胞周期失控是癌變的重要原因。p16是近年來發(fā)現(xiàn)的第一個直接參與細(xì)胞周期調(diào)控的抑癌基因，其表達(dá)產(chǎn)物為p16蛋白. p16基因是一種重要的抑癌基因，在正常細(xì)胞中起負(fù)反饋?zhàn)饔?，?dāng)p16基因突變或丟失時，細(xì)胞增殖失去控制使細(xì)胞無限制地增殖。 p16主要功能是通過抑制CDK4而阻止細(xì)胞由G1期進(jìn)入S期，使細(xì)胞增殖受到限制。用于各種惡性腫瘤如肺癌、惡黑、乳腺癌的研究。目前的研究細(xì)胞周期依賴激酶抑制p16INK4a蛋白在宮頸上皮內(nèi)病變(CIN)中作為一個新標(biāo)記物. p16INK4a的過表達(dá)與HPV E7區(qū)(病毒早期蛋白即病毒致癌基因編碼區(qū))活性有密切相關(guān)性。 p16/CDKN2基因是新近發(fā)現(xiàn)的腫瘤抑制基因，已有研究表明該基因在許多腫瘤出現(xiàn)缺失、突變或重排現(xiàn)象. |
